Statins and safety: Overview for patient care

Hypercholesterolemia is one of the major modifiable risk factors for coronary heart disease. To reach target cholesterol levels, many patients require a combination of lifestyle changes and lipid-lowering therapy.¹ Over the last decade clinical trials have demonstrated that low-density lipoprotein cholesterol (LDL-C) reduction with statin therapy decreases the risk of cardiac events substantially in patients with coronary heart disease, including those with normal cholesterol levels,^2,3 and in healthy high-risk patients irrespective of serum cholesterol level.^4,5

References are listed at the end of the Data Alert.

04DA_SAFETY.ppt

Download 04DA_SAFETY.ppt (6 slides - 1.3MB)

Data_Alert.pdf (1.5MB)

coronary hypercholesterolemia modifiable safety statins

Related at vwbg.org

ASCOT-LLA: Extending benefits of statins to hypertensive patients

Hypertension and hypercholesterolemia frequently coexist and the interaction of these important risk factors increases cardiovascular risk considerably.

ASTEROID trial

Results from ASTEROID: A Study to evaluate the Effect of Rosuvastatin On Intravascular ultrasound-Derived coronary atheroma burden

High-dose statins and early benefit in ACS: Role of inflammation

This monograph, High-dose statins and early benefit in ACS: Role of inflammation , is offered as part of a series of continuing medical education activities from the University of Florida College of Medicine.

More related